Biond Biologics
Biond Biologics is an Israeli clinical-stage biopharmaceutical company developing breakthrough immunotherapies and a pioneering intracellular drug delivery platform for cancer treatment. They focus on innovative biological products targeting immune evasion mechanisms and utilize their INspire platform for intracellular delivery of biologics, aiming to develop life-changing therapies for cancer patients based on scientific research.
Industries
Nr. of Employees
small (1-50)
Patents
Products
ILT2-targeting immune checkpoint monoclonal antibody (checkpoint inhibitor)
An ILT2-blocking monoclonal antibody designed to inhibit an inhibitory receptor expressed in the tumor microenvironment to enhance innate and adaptive anti-tumor immunity.
ILT3 antagonist monoclonal antibody
An antibody designed to bind ILT3 on suppressive myeloid cells and to inhibit their immunosuppressive activity, restoring T cell activation in preclinical models.
Single-domain antibody to prevent CD28 shedding
A small-format antibody engineered to sterically block proteolytic cleavage of CD28, intended to preserve membrane CD28 density and overcome resistance to PD-1 blockade.
Recombinant suppressive fusion protein for autoimmune modulation
A recombinant monomeric fusion protein derived from an endogenous regulatory protein that binds inhibitory Fc receptors and suppresses activation of T, B and dendritic cells.
Anti-KRAS G12D intracellular biologic inhibitor
A biologic designed to selectively target mutant KRAS G12D by blocking protein-protein interactions after intracellular delivery of the payload.
Pan-KRAS intracellular biologic inhibitor
A biologic intended to inhibit both wild-type and multiple mutant KRAS forms after intracellular delivery, enabling broader patient coverage.
ILT2-targeting immune checkpoint monoclonal antibody (checkpoint inhibitor)
An ILT2-blocking monoclonal antibody designed to inhibit an inhibitory receptor expressed in the tumor microenvironment to enhance innate and adaptive anti-tumor immunity.
ILT3 antagonist monoclonal antibody
An antibody designed to bind ILT3 on suppressive myeloid cells and to inhibit their immunosuppressive activity, restoring T cell activation in preclinical models.
Single-domain antibody to prevent CD28 shedding
A small-format antibody engineered to sterically block proteolytic cleavage of CD28, intended to preserve membrane CD28 density and overcome resistance to PD-1 blockade.
Recombinant suppressive fusion protein for autoimmune modulation
A recombinant monomeric fusion protein derived from an endogenous regulatory protein that binds inhibitory Fc receptors and suppresses activation of T, B and dendritic cells.
Anti-KRAS G12D intracellular biologic inhibitor
A biologic designed to selectively target mutant KRAS G12D by blocking protein-protein interactions after intracellular delivery of the payload.
Pan-KRAS intracellular biologic inhibitor
A biologic intended to inhibit both wild-type and multiple mutant KRAS forms after intracellular delivery, enabling broader patient coverage.
Services
Partnering on therapeutic discovery, development and commercialization through licensing and co-development agreements with pharmaceutical companies.
Execution of multicenter Phase 1/2 dose-escalation and expansion trials with integrated PK/PD and biomarker sampling workflows.
Partnering on therapeutic discovery, development and commercialization through licensing and co-development agreements with pharmaceutical companies.
Execution of multicenter Phase 1/2 dose-escalation and expansion trials with integrated PK/PD and biomarker sampling workflows.
Expertise Areas
- Immuno-oncology drug development
- Intracellular biologics delivery
- Antibody and nanobody therapeutics
- Translational biomarker discovery
Key Technologies
- Carrier-mediated intracellular delivery of biologics
- Antibody engineering (monoclonal and VHH formats)
- Recombinant fusion protein design
- Conjugation chemistry for payload-carrier constructs
News & Updates
Dr. Tehila Ben Moshe, Our CEO is presenting at the IO360° Summit - Immuno-Oncology 360 Conference. She will give two talks on BND-35 and INspire platform technology.
Dr. Lilach Chen presented on INspire platform and its application in reducing solid tumor size in mouse models.
Ilana Mandel presented on intracellular delivery of biological agents at Biomed 2023.
Avidor Shulman presented on INspire platform for biologics delivery into cells.
Tehila Ben Moshe and Ori Shilo participated in the conference in San Francisco.
Presented pre-clinical translational data of SAR444881 (BND-22) at ASCO 2022.
Dr. Tehila Ben Moshe, Our CEO is presenting at the IO360° Summit - Immuno-Oncology 360 Conference. She will give two talks on BND-35 and INspire platform technology.
Dr. Lilach Chen presented on INspire platform and its application in reducing solid tumor size in mouse models.
Ilana Mandel presented on intracellular delivery of biological agents at Biomed 2023.
Avidor Shulman presented on INspire platform for biologics delivery into cells.
Tehila Ben Moshe and Ori Shilo participated in the conference in San Francisco.
Presented pre-clinical translational data of SAR444881 (BND-22) at ASCO 2022.